Healthcare

The firm focuses on sectors heavily regulated by governments, in which the government is also the biggest spender.

Regulatory stability, an abundance of dry powder and a strong pipeline of assets make medtech a compelling place to put capital to work, says DC Advisory’s Manish Gupta.

Things have gotten better in the industry, with North American funds taking the lead.

Private equity funds are only starting to come back to dealmaking after shift in the landscape.

Spiraling pharmacy costs are creating a value creation opportunity for PE firms that are able to curb spending, says RX Benefits business development executive Will Statham.

The California pension’s staff want to continue its co-investment program with Ardian and add develop similar programs with the firm outside private equity

WindRose Health Investors VII is set to raise 27% more than its predecessor, closed in 2023 at more than $1.4bn.

Healthcare Fund VI closed at over $625 million and Search Fund II raised almost $225 million.

The firm has returned billions in capital to investors since early 2024, according to the firm’s co-head of North America private equity.